What is the Hester Biosciences PE ratio today?
Hester Biosciences' PE ratio is 14.4 at the 29 October 2026 close (₹2,307.60 a share): a market capitalisation of ₹1,963 crore divided by consolidated net profit of ₹136 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹55.6 crore) it is 35.3. These four quarters include net exceptional items of ₹88.3 crore (one-off gains reported separately), so the ratio on recurring profit would differ.
What is the Hester Biosciences PB ratio (price to book value)?
Hester Biosciences' price-to-book (PB) ratio is 5.45 at the 29 October 2026 close: a market capitalisation of ₹1,963 crore divided by shareholders' equity (book value) of ₹360 crore on 31 March 2026. That is a book value of ₹423.46 per share against a share price of ₹2,307.60.
What is the Hester Biosciences ROE and ROCE?
In FY26, Hester Biosciences' return on equity (ROE) was 16.5% and its return on capital employed (ROCE) was 12.9%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 9.1% and ROCE 8.2%.
What is the Hester Biosciences market cap?
Hester Biosciences' market capitalisation was ₹1,963 crore at the 29 October 2026 close: 85.07 lakh shares at ₹2,307.60 each.
Is Hester Biosciences debt free?
No. Hester Biosciences had borrowings of ₹188 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.51. Its cash and current investments were ₹6.5 crore, so its net debt was ₹182 crore.
What is the Hester Biosciences dividend in 2026 and its record date?
In 2026, Hester Biosciences has declared one dividend: ₹11 with record date 14 July 2026.
What is the Hester Biosciences debt to equity ratio?
Hester Biosciences' debt-to-equity ratio was 0.51 on 31 March 2026: borrowings of ₹188 crore against total equity of ₹368 crore. A year earlier, on 31 March 2025, it was 0.64.
What is the Hester Biosciences net worth?
Hester Biosciences' net worth — shareholders' equity in its consolidated balance sheet — was ₹360 crore on 31 March 2026, up 14.6% from ₹314 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹1,963 crore at the 29 October 2026 close.
What is the Hester Biosciences dividend yield?
Hester Biosciences' dividend yield is 0.48% at the 29 October 2026 close: dividends of ₹11 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹2,307.60. They were ₹11 on 14 July 2026.
What is the Hester Biosciences book value per share?
Hester Biosciences' book value per share was ₹423.46 on 31 March 2026: shareholders' equity of ₹360 crore divided by the 85.07 lakh shares in issue, up 14.6% from ₹369.41 a year earlier. The share price at the 29 October 2026 close was ₹2,307.60.
What is the Hester Biosciences promoter holding?
Promoters held 44.28% of Hester Biosciences on 30 September 2026, down 9.45 percentage points from 53.73% the previous quarter and down 9.45 percentage points from 53.73% a year earlier, according to the shareholding pattern filed with NSE.
What are the Hester Biosciences latest quarterly results?
Hester Biosciences' latest results are for Q1 FY27 (April–June 2026), filed on 30 July 2026: consolidated net profit ₹97 crore, up 489.8% from ₹16.4 crore in Q1 FY26; revenue from operations ₹77.2 crore, down 8.2% year on year.
What is the Hester Biosciences EPS?
Hester Biosciences' basic earnings per share (EPS) were ₹67.57 in FY26, against ₹33.89 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹160.95.
What is the Hester Biosciences free cash flow?
In FY26, Hester Biosciences generated ₹64.1 crore of cash from operations and spent ₹17.8 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹46.3 crore. In FY25 it was ₹43.9 crore.
When are the Hester Biosciences next results?
Hester Biosciences will announce its Q2 FY27 results (July–September 2026) on Thursday, 5 November 2026, the date of the board meeting it has notified to the exchanges.
What is the Hester Biosciences shareholding pattern?
On 30 September 2026, Hester Biosciences' shares were held by promoters 44.28%, foreign portfolio investors (FII/FPI) 0.31%, domestic institutions (DII) 0.08% (including mutual funds at 0.00%) and retail and other non-institutional investors 55.33%. Over the year, FII holding was down 0.22 percentage points from 0.53% and DII holding was up 0.08 percentage points from 0.00%.
What is the Hester Biosciences revenue and profit in FY26?
In FY26 (April 2025–March 2026), Hester Biosciences' consolidated net profit was ₹55.6 crore, up 102.4% from ₹27.5 crore in FY25, on revenue from operations of ₹333 crore (up 6.9%). Over three years, from FY23, net profit was up 109.0%.
How does the Hester Biosciences PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit, Hester Biosciences' PE ratio is 35.3, the highest of the four: Windlas Biotech 29.3, Syncom Formulations 25.1 and NGL Fine-Chem 33.5, a peer average of 29.3. Each is the company's market capitalisation at that price divided by its FY26 net profit.
How does Hester Biosciences compare with its peers?
On FY26 consolidated figures, against Windlas Biotech, Syncom Formulations and NGL Fine-Chem: Hester Biosciences' operating margin of 20.4% is the highest of the four (Windlas Biotech 8.2%, Syncom Formulations 14.5%, NGL Fine-Chem 10.6%; peer average 11.1%); its return on equity of 16.5% is the second highest of the four (Windlas Biotech 12.2%, Syncom Formulations 20.2%, NGL Fine-Chem 15.7%; peer average 16.1%); its revenue growth over three years of 7.7% a year is the lowest of the four (Windlas Biotech 20.8% a year, Syncom Formulations 29.7% a year, NGL Fine-Chem 21.7% a year; peer average 24.1% a year).
Hester Biosciences vs Windlas Biotech: how do they compare?
In FY26, Hester Biosciences earned net profit of ₹55.6 crore on revenue of ₹333 crore, against ₹66.5 crore on ₹904 crore for Windlas Biotech. Hester Biosciences' operating margin was 20.4% (Windlas Biotech 8.2%) and its return on equity 16.5% (Windlas Biotech 12.2%). At the 29 October 2026 close, Hester Biosciences' market capitalisation was ₹1,963 crore against ₹1,949 crore for Windlas Biotech, and its PE ratio on FY26 profit 35.3 against 29.3.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
